Critical Review: Black Titan (BTTC) & Its Competitors

Black Titan (NASDAQ:BTTC) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its competitors? We will compare Black Titan to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Volatility and Risk

Black Titan has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s competitors have a beta of 0.54, meaning that their average stock price is 46% less volatile than the S&P 500.

Earnings and Valuation

This table compares Black Titan and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$2.68 million	-$4.71 million	-0.58
Black Titan Competitors	$240.45 million	-$56.06 million	-10.78

Black Titan’s competitors have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for Black Titan and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	97	199	217	14	2.28

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 130.59%. Given Black Titan’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Black Titan has less favorable growth aspects than its competitors.

Profitability

This table compares Black Titan and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-37.96%	-997.94%	-64.24%

Insider and Institutional Ownership

57.9% of shares of all “Services – Computer Programming And Data Processing” companies are owned by institutional investors. 53.7% of Black Titan shares are owned by insiders. Comparatively, 20.6% of shares of all “Services – Computer Programming And Data Processing” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Black Titan competitors beat Black Titan on 7 of the 13 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.